{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T13:12:16Z","timestamp":1759756336830,"version":"build-2065373602"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Proteom"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1186\/s12014-025-09557-1","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T12:40:53Z","timestamp":1759754453000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Quantitative proteomics identifies conserved proteins and altered regulation of mucin-16 in low grade serous ovarian cancers"],"prefix":"10.1186","volume":"22","author":[{"given":"Christopher M.","family":"Tarney","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulette","family":"Mhawech-Fauceglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan D.","family":"Ogata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamara","family":"Abulez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip A.","family":"Branton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saeid","family":"Movahedi-Lankarani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian L.","family":"Hood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly A.","family":"Conrads","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kendal","family":"Rosalik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwong-Kwok","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Gershenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanghoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil K.","family":"Sood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Robert C.","family":"Bast","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen M.","family":"Darcy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil T.","family":"Phippen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. Larry","family":"Maxwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas P.","family":"Conrads","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas W.","family":"Bateman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"9557_CR1","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3322\/caac.21456","volume":"68","author":"LA Torre","year":"2018","unstructured":"Torre LA, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68:284\u201396. https:\/\/doi.org\/10.3322\/caac.21456.","journal-title":"CA Cancer J Clin"},{"key":"9557_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349. https:\/\/doi.org\/10.3322\/caac.21820.","journal-title":"CA Cancer J Clin"},{"key":"9557_CR3","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.ygyno.2019.12.033","volume":"156","author":"B Slomovitz","year":"2020","unstructured":"Slomovitz B, et al. Low-grade serous ovarian cancer: state of the science. Gynecol Oncol. 2020;156:715\u201325. https:\/\/doi.org\/10.1016\/j.ygyno.2019.12.033.","journal-title":"Gynecol Oncol"},{"key":"9557_CR4","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/PAS.0000000000001419","volume":"44","author":"S Zarei","year":"2020","unstructured":"Zarei S, et al. Clinicopathologic, immunohistochemical, and molecular characteristics of ovarian serous carcinoma with mixed morphologic features of high-grade and low-grade serous carcinoma. Am J Surg Pathol. 2020;44:316\u201328. https:\/\/doi.org\/10.1097\/PAS.0000000000001419.","journal-title":"Am J Surg Pathol"},{"key":"9557_CR5","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(21)02175-9","volume":"399","author":"DM Gershenson","year":"2022","unstructured":"Gershenson DM, et al. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281\/LOGS): an international, randomised, open-label, multicentre, phase 2\/3 trial. Lancet. 2022;399:541\u201353. https:\/\/doi.org\/10.1016\/S0140-6736(21)02175-9.","journal-title":"Lancet"},{"key":"9557_CR6","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1186\/s12967-022-03820-x","volume":"20","author":"KK Wong","year":"2022","unstructured":"Wong KK, et al. Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors. J Transl Med. 2022;20:606. https:\/\/doi.org\/10.1186\/s12967-022-03820-x.","journal-title":"J Transl Med"},{"key":"9557_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/path.6338","author":"R Vallejos","year":"2024","unstructured":"Vallejos R, et al. Changes in the tumour microenvironment mark the transition from serous borderline tumour to low-grade serous carcinoma. J Pathol. 2024. https:\/\/doi.org\/10.1002\/path.6338.","journal-title":"J Pathol"},{"key":"9557_CR8","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1093\/carcin\/bgab010","volume":"42","author":"P Giamougiannis","year":"2021","unstructured":"Giamougiannis P, Martin-Hirsch PL, Martin FL. The evolving role of MUC16 (CA125) in the transformation of ovarian cells and the progression of neoplasia. Carcinogenesis. 2021;42:327\u201343. https:\/\/doi.org\/10.1093\/carcin\/bgab010.","journal-title":"Carcinogenesis"},{"issue":"2","key":"9557_CR9","doi-asserted-by":"publisher","first-page":"107502","DOI":"10.1016\/j.celrep.2020.03.066","volume":"31","author":"S Lee","year":"2020","unstructured":"Lee S, et al. Molecular analysis of clinically defined subsets of high-grade serous ovarian cancer. Cell Rep. 2020;31(2):107502. https:\/\/doi.org\/10.1016\/j.celrep.2020.03.066.","journal-title":"Cell Rep"},{"key":"9557_CR10","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41588-023-01320-2","volume":"55","author":"NL Burdett","year":"2023","unstructured":"Burdett NL, et al. Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer. Nat Genet. 2023;55:437\u201350. https:\/\/doi.org\/10.1038\/s41588-023-01320-2.","journal-title":"Nat Genet"},{"key":"9557_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47. https:\/\/doi.org\/10.1093\/nar\/gkv007.","journal-title":"Nucleic Acids Res"},{"key":"9557_CR12","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545\u201350. https:\/\/doi.org\/10.1073\/pnas.0506580102.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9557_CR13","doi-asserted-by":"publisher","first-page":"e0294236","DOI":"10.1371\/journal.pone.0294236","volume":"18","author":"D Tang","year":"2023","unstructured":"Tang D, et al. SRplot: a free online platform for data visualization and graphing. PLoS One. 2023;18:e0294236. https:\/\/doi.org\/10.1371\/journal.pone.0294236.","journal-title":"PLoS One"},{"key":"9557_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.108978","volume":"35","author":"HQ Dinh","year":"2021","unstructured":"Dinh HQ, et al. Single-cell transcriptomics identifies gene expression networks driving differentiation and tumorigenesis in the human fallopian tube. Cell Rep. 2021;35:108978. https:\/\/doi.org\/10.1016\/j.celrep.2021.108978.","journal-title":"Cell Rep"},{"key":"9557_CR15","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1242\/dev.149989","volume":"144","author":"A Ghosh","year":"2017","unstructured":"Ghosh A, Syed SM, Tanwar PS. In vivo genetic cell lineage tracing reveals that oviductal secretory cells self-renew and give rise to ciliated cells. Development. 2017;144:3031\u201341. https:\/\/doi.org\/10.1242\/dev.149989.","journal-title":"Development"},{"issue":"1","key":"9557_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18010210","volume":"18","author":"S Yan","year":"2017","unstructured":"Yan S, et al. The potential of targeting ribosome biogenesis in high-grade serous ovarian cancer. Int J Mol Sci. 2017;18. https:\/\/doi.org\/10.3390\/ijms18010210.","journal-title":"Int J Mol Sci"},{"key":"9557_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00728-8","volume":"6","author":"J Kang","year":"2021","unstructured":"Kang J, et al. Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy. Signal Transduct Target Ther. 2021;6:323. https:\/\/doi.org\/10.1038\/s41392-021-00728-8.","journal-title":"Signal Transduct Target Ther"},{"key":"9557_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ejcsup.2019.12.001","volume":"15","author":"R Lopez-Reig","year":"2020","unstructured":"Lopez-Reig R, Lopez-Guerrero JA. The hallmarks of ovarian cancer: proliferation and cell growth. EJC Suppl. 2020;15:27\u201337. https:\/\/doi.org\/10.1016\/j.ejcsup.2019.12.001.","journal-title":"EJC Suppl"},{"key":"9557_CR19","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1023\/a:1026519016213","volume":"18","author":"RC Casey","year":"2000","unstructured":"Casey RC, Skubitz AP. CD44 and beta1 integrins mediate ovarian carcinoma cell migration toward extracellular matrix proteins. Clin Exp Metastasis. 2000;18:67\u201375. https:\/\/doi.org\/10.1023\/a:1026519016213.","journal-title":"Clin Exp Metastasis"},{"key":"9557_CR20","doi-asserted-by":"publisher","first-page":"272","DOI":"10.3892\/ijo.2014.2695","volume":"46","author":"BR Yi","year":"2015","unstructured":"Yi BR, Kim TH, Kim YS, Choi KC. Alteration of epithelial-mesenchymal transition markers in human normal ovaries and neoplastic ovarian cancers. Int J Oncol. 2015;46:272\u201380. https:\/\/doi.org\/10.3892\/ijo.2014.2695.","journal-title":"Int J Oncol"},{"key":"9557_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15143651","author":"EM Ploeg","year":"2023","unstructured":"Ploeg EM, et al. A novel bispecific antibody for EpCAM-directed inhibition of the CD73\/adenosine immune checkpoint in ovarian cancer. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15143651.","journal-title":"Cancers (Basel)"},{"key":"9557_CR22","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ygyno.2024.06.017","volume":"188","author":"MR Mirza","year":"2024","unstructured":"Mirza MR, et al. NSGO-OV-UMB1\/ENGOT-OV30: a phase II study of durvalumab in combination with the anti-CD73 monoclonal antibody oleclumab in patients with relapsed ovarian cancer. Gynecol Oncol. 2024;188:103\u201310. https:\/\/doi.org\/10.1016\/j.ygyno.2024.06.017.","journal-title":"Gynecol Oncol"},{"key":"9557_CR23","doi-asserted-by":"publisher","first-page":"4494","DOI":"10.1158\/0008-5472.CAN-14-3569","volume":"75","author":"M Turcotte","year":"2015","unstructured":"Turcotte M, et al. CD73 is associated with poor prognosis in high-grade serous ovarian cancer. Cancer Res. 2015;75:4494\u2013503. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-3569.","journal-title":"Cancer Res"},{"key":"9557_CR24","doi-asserted-by":"publisher","unstructured":"Wong K-K, Gershenson DM, Abstract. 135: Immunosuppressive microenvironment in low-grade serous ovarian carcinoma. Cancer Research 78, 135\u2013135. https:\/\/doi.org\/10.1158\/1538-7445.am2018-135 (2018).","DOI":"10.1158\/1538-7445.am2018-135"},{"key":"9557_CR25","doi-asserted-by":"publisher","first-page":"704242","DOI":"10.3389\/fcell.2021.704242","volume":"9","author":"T Yue","year":"2021","unstructured":"Yue T, et al. Two similar signatures for predicting the prognosis and immunotherapy efficacy of stomach adenocarcinoma patients. Front Cell Dev Biol. 2021;9:704242. https:\/\/doi.org\/10.3389\/fcell.2021.704242.","journal-title":"Front Cell Dev Biol"},{"key":"9557_CR26","doi-asserted-by":"publisher","first-page":"9759","DOI":"10.1038\/srep09759","volume":"5","author":"S Das","year":"2015","unstructured":"Das S, et al. Membrane proximal ectodomain cleavage of MUC16 occurs in the acidifying Golgi\/post-Golgi compartments. Sci Rep. 2015;5:9759. https:\/\/doi.org\/10.1038\/srep09759.","journal-title":"Sci Rep"},{"key":"9557_CR27","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1515\/hsz-2014-0155","volume":"395","author":"L Bruney","year":"2014","unstructured":"Bruney L, Conley KC, Moss NM, Liu Y, Stack MS. Membrane-type I matrix metalloproteinase-dependent ectodomain shedding of mucin16\/ CA-125 on ovarian cancer cells modulates adhesion and invasion of peritoneal mesothelium. Biol Chem. 2014;395:1221\u201331. https:\/\/doi.org\/10.1515\/hsz-2014-0155.","journal-title":"Biol Chem"},{"key":"9557_CR28","doi-asserted-by":"publisher","first-page":"11079","DOI":"10.1074\/jbc.M116.770123","volume":"292","author":"T Taniguchi","year":"2017","unstructured":"Taniguchi T, et al. N-glycosylation affects the stability and barrier function of the MUC16 mucin. J Biol Chem. 2017;292:11079\u201390. https:\/\/doi.org\/10.1074\/jbc.M116.770123.","journal-title":"J Biol Chem"},{"key":"9557_CR29","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1006\/gyno.1996.0301","volume":"63","author":"I But","year":"1996","unstructured":"But I, Gorisek B. Preoperative value of CA 125 as a reflection of tumor grade in epithelial ovarian cancer. Gynecol Oncol. 1996;63:166\u201372. https:\/\/doi.org\/10.1006\/gyno.1996.0301.","journal-title":"Gynecol Oncol"},{"key":"9557_CR30","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1111\/j.1432-0436.2008.00295.x","volume":"76","author":"Y Wang","year":"2008","unstructured":"Wang Y, et al. MUC16 expression during embryogenesis, in adult tissues, and ovarian cancer in the mouse. Differentiation. 2008;76:1081\u201392. https:\/\/doi.org\/10.1111\/j.1432-0436.2008.00295.x.","journal-title":"Differentiation"},{"key":"9557_CR31","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1097\/ACI.0b013e32830e6b04","volume":"8","author":"F Mantelli","year":"2008","unstructured":"Mantelli F, Argueso P. Functions of ocular surface mucins in health and disease. Curr Opin Allergy Clin Immunol. 2008;8:477\u201383. https:\/\/doi.org\/10.1097\/ACI.0b013e32830e6b04.","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"9557_CR32","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/1476-4598-13-129","volume":"13","author":"M Felder","year":"2014","unstructured":"Felder M, et al. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Mol Cancer. 2014;13:129. https:\/\/doi.org\/10.1186\/1476-4598-13-129.","journal-title":"Mol Cancer"},{"key":"9557_CR33","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.21037\/atm-20-6388","volume":"8","author":"Y Zhai","year":"2020","unstructured":"Zhai Y, et al. MUC16 affects the biological functions of ovarian cancer cells and induces an antitumor immune response by activating dendritic cells. Ann Transl Med. 2020;8:1494. https:\/\/doi.org\/10.21037\/atm-20-6388.","journal-title":"Ann Transl Med"},{"key":"9557_CR34","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/path.5036","volume":"244","author":"NW Bateman","year":"2018","unstructured":"Bateman NW, Conrads TP. Recent advances and opportunities in proteomic analyses of tumour heterogeneity. J Pathol. 2018;244:628\u201337. https:\/\/doi.org\/10.1002\/path.5036.","journal-title":"J Pathol"}],"container-title":["Clinical Proteomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12014-025-09557-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12014-025-09557-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12014-025-09557-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T12:40:54Z","timestamp":1759754454000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalproteomicsjournal.biomedcentral.com\/articles\/10.1186\/s12014-025-09557-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["9557"],"URL":"https:\/\/doi.org\/10.1186\/s12014-025-09557-1","relation":{},"ISSN":["1542-6416","1559-0275"],"issn-type":[{"value":"1542-6416","type":"print"},{"value":"1559-0275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]},"assertion":[{"value":"15 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Formalin-fixed, paraffin-embedded (FFPE) LGSOC and HGSOC tumor and normal fallopian tube tissues were obtained from Inova Fairfax Hospital (Falls Church, VA) under a less than minimal-risk WCG IRB-approved protocol #20122048 with waivers for consent and HIPAA authorization and evaluated under protocol #14-1679 with an exempt determination by the WCG IRB in accordance with the use of de-identified data under US Federal regulation 45 CFR 46.102(f).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The views expressed herein are those of the authors and do not reflect the official policy of the Uniformed Services University of the Health Sciences, the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Inova Health System, the Department of Army\/Navy\/Air Force, Department of Defense, or U.S. Government. Mention of trade names, commercial products, or organizations does not imply endorsement by the U.S. Government.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}],"article-number":"33"}}